Evenity (Romosozumab) vs Tymlos (Abaloparatide): What the Real-World Evidence Actually Shows for Women

Why These Two Drugs Get Compared

Both Evenity and Tymlos sit in the anabolic tier of osteoporosis treatment, the category reserved for women whose bone density is so low, or whose fracture history is so serious, that a standard antiresorptive like alendronate alone is not enough. They are not competing drugs in the usual sense; they have different mechanisms, different administration schedules, and different risk profiles. Still, clinicians and patients frequently weigh one against the other when deciding on a first anabolic agent or when considering a switch after one course has ended.

Understanding the difference matters because anabolic therapy is time-limited. You get one or two windows to use bone-building drugs before you are committed to lifelong antiresorptive maintenance. Choosing the right window, for the right drug, changes your long-term fracture trajectory.

How Each Drug Works

Romosozumab (Evenity): Dual Action in One Injection

Romosozumab is a monoclonal antibody that blocks sclerostin, a protein made by osteocytes that normally brakes bone formation. Blocking sclerostin simultaneously increases bone formation and decreases bone resorption. This dual action is why romosozumab produces BMD gains faster than any other approved anabolic agent in postmenopausal women. The FDA approved romosozumab in April 2019 specifically for postmenopausal women at high or very high fracture risk.

Abaloparatide (Tymlos): PTHrP Analog Targeting Cortical Bone

Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP). It binds preferentially to the RG conformation of the PTH1 receptor, which is thought to favor bone formation over resorption compared to teriparatide. This binding preference appears to produce more pronounced cortical bone density gains, which matters because cortical bone makes up roughly 80% of the skeleton and drives nonvertebral fracture protection. The FDA approved abaloparatide in April 2017 for postmenopausal women at high fracture risk.

The Key Trial Data Side by Side

ARCH Trial: Romosozumab vs. Alendronate

The ARCH trial (Miller et al., NEJM 2017) enrolled 4,093 postmenopausal women with a mean age of 74 and a prior vertebral fracture. Participants received either romosozumab 210 mg monthly or weekly alendronate for 12 months, then all switched to alendronate. At 24 months, romosozumab followed by alendronate reduced new vertebral fractures by 48% relative to alendronate alone. Nonvertebral fracture risk fell by 19%, and hip fracture risk fell by 38% compared to the alendronate-only group. These are the fracture-reduction numbers that established romosozumab as the highest-efficacy option available for spine fractures.

The cardiovascular signal in ARCH is real and cannot be minimized. Serious cardiovascular events (heart attack, stroke, cardiovascular death) occurred in 2.5% of the romosozumab group vs. 1.9% of the alendronate group over the 12-month active-treatment phase. This led to the FDA boxed warning that romosozumab should not be initiated within 12 months of a myocardial infarction or stroke.

ACTIVE Trial: Abaloparatide vs. Teriparatide vs. Placebo

The ACTIVE trial (Leder et al., JAMA 2016) enrolled 2,463 postmenopausal women with a mean age of 69 and low BMD or prior fracture. At 18 months, abaloparatide reduced new vertebral fractures by 86% vs. Placebo and nonvertebral fractures by 43% vs. Placebo. Compared directly to teriparatide, abaloparatide produced a significantly greater reduction in nonvertebral fractures (43% vs. 28% for teriparatide vs. Placebo) and drove larger total hip BMD gains (+3.6% vs. +1.1% for teriparatide at 18 months). Hypercalcemia was substantially less common with abaloparatide than teriparatide (3.4% vs. 6.4%).

Real-World Evidence: What Happens Outside Clinical Trials

Head-to-head real-world data directly comparing romosozumab and abaloparatide in the same cohort does not yet exist in the peer-reviewed literature. This is an important evidence gap. What we have are separate real-world studies for each drug, insurance and claims database analyses, and registry data, none of which were designed to compare the two agents against each other. The framework below synthesizes that separate literature to give you the most accurate picture currently possible.

Real-World Romosozumab Data

A 2022 retrospective cohort analysis using US insurance claims data found that persistence with romosozumab at 12 months was approximately 62%, meaning roughly one in three women did not complete the full 12-injection course. The most common reason was prior authorization denial or cost burden; clinical side effects were less frequently cited. Because romosozumab's fracture benefits depend on completing all 12 doses, low persistence is clinically significant.

In the real world, the cardiovascular boxed warning has meaningfully changed prescribing patterns. Cardiologists are often consulted before initiation in women over 65 with any cardiac history, adding weeks to the prescribing timeline. Older postmenopausal women, who have the highest fracture risk, are also the group most likely to have pre-existing cardiovascular disease, creating a prescribing paradox.

Real-World Abaloparatide Data

Observational data published in Osteoporosis International (2021) found that real-world fracture reduction with abaloparatide in postmenopausal women closely mirrored ACTIVE trial results over 18 months of follow-up. Adherence was notably higher than historical teriparatide data, likely because the auto-injector pen has a shorter needle and fewer gastrointestinal side effects. Dizziness and palpitations remained the most reported adverse effects in the first weeks of use, consistent with trial data.

A separate claims analysis found that women who completed 18 to 24 months of abaloparatide and then transitioned to denosumab had sustained hip BMD gains at 24 months post-transition, supporting the sequential strategy recommended by most guidelines.

Sex-Specific Physiology: Why Women's Bodies Respond Differently

Bone biology in women is inseparable from hormonal status. Estrogen is the dominant suppressor of osteoclast activity. When estrogen falls at menopause, osteoclast-driven resorption accelerates, and women can lose 1 to 3% of bone density per year in the first five years after the final menstrual period. This is the window during which anabolic therapy delivers the largest absolute gain.

Both romosozumab and abaloparatide were studied almost exclusively in postmenopausal women, so the trial data is genuinely sex-specific. There are no large trial datasets in premenopausal women or perimenopausal women for either drug, which means any use in those groups is extrapolated from postmenopausal pharmacokinetics.

Cortical vs. Trabecular Bone in Women

Women's fracture pattern differs from men's. Vertebral and hip fractures dominate in postmenopausal women, and cortical thinning at the hip is a major driver of hip fracture risk. Abaloparatide's relatively stronger effect on cortical bone, demonstrated by its superior total hip BMD gains in ACTIVE, may translate to clinically meaningful hip fracture protection in women whose hip BMD is the primary concern. Romosozumab's dual mechanism produces large trabecular gains, making it a strong choice when vertebral fracture is the immediate concern, such as in a woman with multiple prior spinal compression fractures.

Menstrual Cycle and Hormonal Status

Neither drug is used during the reproductive years in standard practice. If a perimenopausal woman has severe, glucocorticoid-induced, or premenopausal osteoporosis requiring anabolic therapy, the decision is typically made on a case-by-case basis in consultation with a reproductive endocrinologist. No pharmacokinetic studies of romosozumab or abaloparatide have been conducted in cycling women, and the hormonal fluctuations of perimenopause are not accounted for in any current dosing guidance.

Pregnancy, Lactation, and Contraception

Both romosozumab and abaloparatide are contraindicated in pregnancy. Neither drug is indicated for use in premenopausal women as standard practice, but if a woman of reproductive age receives either agent for a rare clinical indication (such as severe premenopausal osteoporosis), reliable contraception is mandatory throughout treatment.

Romosozumab in pregnancy: Animal studies showed fetal harm at doses comparable to clinical exposure. There are no adequate human pregnancy data. The FDA label for romosozumab classifies it as contraindicated in pregnancy. The drug has a long half-life of approximately 6.4 days, and sclerostin signaling is active in fetal bone development, raising theoretical teratogenic concern.

Abaloparatide in pregnancy: Animal reproductive studies showed skeletal and cardiac abnormalities at doses above clinical exposure. Human data are absent. The FDA label for abaloparatide lists pregnancy as a contraindication. Given that PTHrP is endogenously produced during pregnancy and has biological activity in fetal calcium metabolism, exogenous PTHrP analogs carry theoretical risk even at therapeutic doses.

Lactation: Neither drug has lactation transfer data in humans. Both are large-molecule biologics or peptides; meaningful oral bioavailability in a breastfed infant is unlikely but unstudied. Neither drug is recommended during breastfeeding given the lack of safety data. Women should discuss the risk-benefit balance with their prescriber.

These drugs are postmenopausal therapies. The practical pregnancy and lactation question arises most often when a woman treated for rare premenopausal osteoporosis later wishes to conceive. A washout period of at least one to two months is commonly advised before attempting conception given half-life considerations, though no formal guidance exists.

Who This Is Right For (and Who It Is Not)

Romosozumab Is More Likely the Right Choice If:

• You have had multiple vertebral fractures and need maximal spine BMD gain quickly
• Your T-score is extremely low (below negative 3.0) and you want the fastest bone-building course available
• You do not have a history of myocardial infarction or stroke in the past 12 months
• You can commit to 12 monthly clinic visits for administered injections
• Prior antiresorptive therapy (alendronate, risedronate) has not adequately controlled fracture risk, making the ARCH active-comparator design clinically relevant to your situation

Romosozumab Is Likely Not Right If:

• You had a heart attack or stroke within the past year (FDA boxed warning, absolute caution)
• You have significant cardiovascular disease and your cardiologist advises against it
• Monthly clinic injections are logistically impossible for you

Abaloparatide Is More Likely the Right Choice If:

• Hip fracture risk is your primary concern, particularly with low total hip or femoral neck BMD
• You want to self-inject at home and manage your own schedule daily
• You have a cardiac history that makes your clinician uncomfortable with romosozumab
• You need up to 24 months of anabolic therapy rather than 12
• Hypercalcemia from teriparatide was a prior problem; abaloparatide's lower hypercalcemia rate makes it a reasonable alternative

Abaloparatide Is Likely Not Right If:

• Daily self-injection is not feasible due to dexterity, vision, or adherence concerns
• Orthostatic hypotension or dizziness is a significant safety issue for you (the drug's palpitation and dizziness side effects in the first 4 hours after each dose matter more if you are at fall risk)
• Cost and insurance access are barriers; both drugs are expensive, but prior authorization requirements differ by plan

Switching: From Evenity to Tymlos or Tymlos to Evenity

Should You Switch from Evenity to Tymlos?

The answer depends on why you are switching. Evenity's course is fixed at 12 months. Once you have completed all 12 injections, you do not start a second romosozumab course. Regulatory approval and clinical guidelines do not support re-treatment with romosozumab. After Evenity, your options are:

1. Transition to an antiresorptive (bisphosphonate or denosumab), which is the standard recommended pathway
2. Transition to abaloparatide if, for some reason, you cannot immediately start an antiresorptive and your fracture risk remains very high

Option 2 is off-label and evidence-sparse. There is no published randomized trial of romosozumab followed by abaloparatide. Mechanistically, following a sclerostin inhibitor with a PTHrP analog is not pharmacologically illogical, since they work through different receptors. A small number of observational reports describe this sequence, but no safety or efficacy data are strong enough to support a clear recommendation. If you and your clinician are considering this, the decision should involve a bone specialist.

Switching from Tymlos to Evenity

This scenario is even less studied. A woman who has completed 18 to 24 months of abaloparatide and then starts romosozumab would be stacking two anabolic courses sequentially. Current American Association of Clinical Endocrinology (AACE) 2020 guidelines do not explicitly address this sequence. The theoretical concern is whether sclerostin inhibition after PTHrP-analog stimulation produces additive, diminishing, or unpredictable BMD effects. Mechanistic data from small studies suggest additive effects are plausible, but no outcomes data confirm fracture reduction. This sequence should not be assumed safe or effective without specialist input.

What the Guidelines Actually Say About Sequencing

The Endocrine Society 2019 clinical practice guideline on osteoporosis in postmenopausal women recommends that anabolic therapy be followed by antiresorptive therapy to preserve BMD gains and prevent the rebound resorption seen when anabolic agents are stopped without a bridge. The American Association of Clinical Endocrinology 2020 guidelines further stratify fracture risk and recommend very high risk women consider anabolic-first strategies. Neither guideline endorses sequential dual-anabolic therapy as a standard approach. It remains a clinical decision made on an individual basis.

PCOS, Glucocorticoid Use, and Other Female-Specific Bone Concerns

PCOS and Bone Health

Women with PCOS are not at substantially elevated osteoporosis risk during their reproductive years, primarily because androgen excess (and often higher BMI) partially protects trabecular bone. If, however, a woman with PCOS undergoes premature ovarian insufficiency or requires long-term glucocorticoid therapy for a comorbid autoimmune condition, bone loss can accelerate. Anabolic therapy may be considered in those rare scenarios, though no PCOS-specific trial data for either romosozumab or abaloparatide exist.

Glucocorticoid-Induced Osteoporosis

Glucocorticoid-induced osteoporosis (GIOP) is a female-predominant clinical problem, partly because autoimmune conditions requiring long-term steroids disproportionately affect women. Teriparatide has the most trial data in GIOP. Abaloparatide's use in GIOP is extrapolated from its postmenopausal data. Romosozumab's use in GIOP remains investigational. Women on long-term glucocorticoids should discuss which anabolic agent has the most directly applicable evidence with a bone specialist.

Postmenopausal Women with Prior Breast Cancer

Both drugs are approved for postmenopausal women regardless of breast cancer history, but women who have been treated with aromatase inhibitors (AIs) for hormone-receptor-positive breast cancer face accelerated bone loss and may be candidates for anabolic therapy earlier than typical. The ASCO/CCO 2019 guideline on bone health in breast cancer survivors supports anabolic therapy when T-score falls below negative 2.5 or fractures occur on AI therapy. Neither drug is contraindicated in breast cancer survivors, and no evidence suggests either drives breast cancer recurrence.

Cost, Access, and Practical Considerations

Drug cost is a real barrier. Romosozumab's annual course (12 injections) carries a list price exceeding $20,000 in the US. Abaloparatide's 18-to-24-month course carries a comparable or slightly higher total cost at list price. Both manufacturers offer patient assistance programs, and Medicare Part D covers both with prior authorization. Women with Medicare should check their specific plan formulary; tier placement varies.

Romosozumab requires monthly clinic or infusion-center visits, which adds transportation and time burden. For women in rural areas or with mobility limitations from existing fractures, the logistics of 12 clinic visits in 12 months are genuinely challenging. Abaloparatide's daily home self-injection resolves the access problem for many women but introduces the need for injection training and daily adherence.

Insurance prior authorization for both drugs typically requires documented T-score at or below negative 2.5, a prior fracture history, or documented failure of oral bisphosphonate therapy. Some plans require teriparatide failure before approving either newer anabolic agent, an increasingly contested restriction given teriparatide's inferior nonvertebral fracture data compared to abaloparatide.

Evidence Gaps Specific to Women

Trials for both drugs enrolled almost exclusively postmenopausal women aged 55 to 90. This means:

• Perimenopausal women with severe osteoporosis have no direct trial data for either drug.
• Women of color were underrepresented in both ARCH and ACTIVE. ARCH enrolled about 12% non-White participants; ACTIVE enrolled about 18%. Whether BMD response or fracture reduction differs by race or ethnicity is not adequately characterized.
• Women with prior bariatric surgery face different calcium absorption and bone metabolism challenges. Neither trial specifically analyzed this subgroup.
• Women with chronic kidney disease (CKD) stage 3b or higher were largely excluded from both trials. Abaloparatide is not recommended with estimated GFR below 30. Romosozumab data in advanced CKD are limited.

These are honest gaps, not speculative ones. If you belong to any of these groups, your prescriber is working with evidence that was not generated in a population that looks like you.